Kiyatec is disrupting cancer care by providing oncologists with a functional precision assay that accurately predicts patient–specific therapeutic response and non–response before treatment begins.
Kiyatec is a leader in functional precision oncology. Kiyatec utilizes proprietary platforms across multiple solid tumor types, based on robust science that scores >95th percentile in peer reviewed journals.
Our Science & Technology Provide Oncologists with Insights to Improve Clinical Outcomes
Our ex vivo 3D cell culture platforms enable us to utilize a patient's live cancer cells from surgical or biopsy tissue to create a patient-specific,
in vivo-like tumor and immune microenvironment, outside the body, to accurately model and assess response (ex vivo efficacy) to investigational and FDA-cleared cancer therapies.
Our unique ex vivo 3D cell culture approach maximizes patient relevance in the laboratory assessment of drug-on-tumor cell interaction prior to therapy administration, providing clinicians with patient-specific therapeutic response prediction in 7-10 business days, prior to initiation of therapy.
Kiyatec offers clinical testing for high-grade glioma and is developing tests for ovarian, breast, non-small cell lung and rare tumors in its CLIA-certified lab. Kiyatec works with leading biopharmaceutical companies to unlock response dynamics for investigational drug candidates for use in solid tumors.